Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market

About this update from Zylox-tonbridge Medical Technology Co., Ltd. Class H

[{"type":"text","content":"Marks a major milestone in Zylox-Tonbridge's long-term commitment to global expansion","length":94,"tagName":"p"},{"type":"text","content":"Builds an integrated global commercialization platform to accelerate Zylox-Tonbridge's adoption of innovative vascular solutions worldwide","length":142,"tagName":"p"},{"type":"text","content":"Delivers Zylox-Tonbridge's manufacturing and operational synergies across Germany and China","length":95,"tagName":"p"},{"type":"text","content":"Fully unlocks Zylox-Tonbridge's high-efficiency R&D capabilities","length":72,"tagName":"p"},{"type":"text","content":"HANGZHOU, China and BERLIN, Jan. 16, 2026 /PRNewswire/ -- Zylox-Tonbridge (HKEX:2190), a Hong Kong-listed medical technology company focused on neuro-and peripheral vascular interventional products and solutions, today announced that it has entered into a definitive agreement to acquire a Germany-based medical technology company, Optimed Medizinische Instrumente GmbH ("Optimed"), specializing in research and development, production and distribution of medical devices for minimally invasive therapy worldwide, in multiple steps. Under the terms of the agreement, Zylox-Tonbridge has the option to acquire the entire equity interest in Optimed from its existing shareholders.","length":693,"tagName":"p"},{"type":"text","content":"Optimed is a leading medical technology company specializing in minimally invasive vascular and endourology devices. Over nearly three decades, Optimed has developed an extensive sales and service network spanning more than 70 countries worldwide and has developed long-standing relationships with physicians and key opinion leaders in Europe and other key markets. Optimed has one of the most comprehensive product portfolios in the peripheral venous stenting market, including specialized devices for the iliofemoral veins, the iliac bifurcation and the vena cava. Optimed's dedicated venous stents are supported by high-evidence clinical trials such as the sinus-Venous, is supported by robust clinical evidence from STEVECO, the first prospective, randomized, multicenter trial in this chronic deep venous obstruction setting, which demonstrated significant improvements in quality of life and clinical severity compared with conservative treatment.","length":957,"tagName":"p"},{"type":"t...

More updates from Zylox-tonbridge Medical Technology Co., Ltd. Class H